|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bruix J, Gores GJ and Mazzaferro V:
Hepatocellular carcinoma: Clinical frontiers and perspectives. Gut.
63:844–855. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Said A and Wells J: Management of
hepatocellular carcinoma. Minerva Med. 100:51–68. 2009.PubMed/NCBI
|
|
5
|
Zhuang L, Xu L, Wang P, Jiang Y, Yong P,
Zhang C, Zhang H, Meng Z and Yang P: Na+/K+-ATPase α1 subunit, a
novel therapeutic target for hepatocellular carcinoma. Oncotarget.
6:28183–28193. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yu SM and Kim SJ: DNA-hypomethylating
agent, 5′-azacytidine, induces cyclooxygenase-2 expression via the
PI3-kinase/Akt and extracellular signal-regulated kinase-1/2
pathways in human HT1080 fibrosarcoma cells. Int J Oncol.
47:1469–1475. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Diab S, Fidanzi C, Léger DY, Ghezali L,
Millot M, Martin F, Azar R, Esseily F, Saab A, Sol V, et al:
Berberis libanotica extract targets NF-κB/COX-2, PI3K/Akt and
mitochondrial/caspase signalling to induce human erythroleukemia
cell apoptosis. Int J Oncol. 47:220–230. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Cao J, Guo T, Dong Q, Zhang J and Li Y:
miR-26b is downregulated in human tongue squamous cell carcinoma
and regulates cell proliferation and metastasis through a
COX-2-dependent mechanism. Oncol Rep. 33:974–980. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wang L, Wang Z, Li J, Zhang W, Ren F and
Yue W: NFATc1 activation promotes the invasion of U251 human
glioblastoma multiforme cells through COX-2. Int J Mol Med.
35:1333–1340. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Liu M, Li CM, Chen ZF, Ji R, Guo QH, Li Q,
Zhang HL and Zhou YN: Celecoxib regulates apoptosis and autophagy
via the PI3K/Akt signaling pathway in SGC-7901 gastric cancer
cells. Int J Mol Med. 33:1451–1458. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yusup G, Akutsu Y, Mutallip M, Qin W, Hu
X, Komatsu-Akimoto A, Hoshino I, Hanari N, Mori M, Akanuma N, et
al: A COX-2 inhibitor enhances the antitumor effects of
chemotherapy and radiotherapy for esophageal squamous cell
carcinoma. Int J Oncol. 44:1146–1152. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Qian M, Qian D, Jing H, Li Y, Ma C and
Zhou Y: Combined cetuximab and celecoxib treatment exhibits a
synergistic anticancer effect on human oral squamous cell carcinoma
in vitro and in vivo. Oncol Rep. 32:1681–1688. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Li J, Chen X, Dong X, Xu Z, Jiang H and
Sun X: Specific COX-2 inhibitor, meloxicam, suppresses
proliferation and induces apoptosis in human HepG2 hepatocellular
carcinoma cells. J Gastroenterol Hepatol. 21:1814–1820. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Dong X, Li R, Xiu P, Dong X, Xu Z, Zhai B,
Liu F, Jiang H, Sun X, Li J and Qiao H: Meloxicam executes its
antitumor effects against hepatocellular carcinoma in
COX-2-dependent and -independent pathways. PLoS One. 9:e928642014.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhong J, Xiu P, Dong X, Wang F, Wei H,
Wang X, Xu Z, Liu F, Li T, Wang Y and Li J: Meloxicam combined with
sorafenib synergistically inhibits tumor growth of human
hepatocellular carcinoma cells via ER stress-related apoptosis.
Oncol Rep. 34:2142–2150. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhong J, Dong X, Xiu P, Wang F, Liu J, Wei
H, Xu Z, Liu F, Li T and Li J: Blocking autophagy enhances
meloxicam lethality to hepatocellular carcinoma by promotion of
endoplasmic reticulum stress. Cell Prolif. 48:691–704. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Shannan B, Seifert M, Leskov K, Willis J,
Boothman D, Tilgen W and Reichrath J: Challenge and promise: Roles
for clusterin in pathogenesis, progression and therapy of cancer.
Cell Death Differ. 13:12–19. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chen Q, Wang Z, Zhang K, Liu X, Cao W,
Zhang L, Zhang S, Yan B, Wang Y and Xia C: Clusterin confers
gemcitabine resistance in pancreatic cancer. World J Surg Oncol.
9:592011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Xiu P, Dong X, Dong X, Xu Z, Zhu H, Liu F,
Wei Z, Zhai B, Kanwar JR, Jiang H, et al: Secretory clusterin
contributes to oxaliplatin resistance by activating Akt pathway in
hepatocellular carcinoma. Cancer Sci. 104:375–382. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Xiu P, Xu Z, Liu F, Li Z, Li T, Zou F, Sun
X and Li J: Downregulating sCLU enhances the sensitivity of
hepatocellular carcinoma cells to gemcitabine by activating the
intrinsic apoptosis pathway. Dig Dis Sci. 59:1798–1809. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wang F, Dong X, Xiu P, Zhong J, Wei H, Xu
Z, Li T, Liu F, Sun X and Li J: T7 peptide inhibits angiogenesis
via downregulation of angiopoietin-2 and autophagy. Oncol Rep.
33:675–684. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhang B, Zhang K, Liu Z, Hao F, Wang M, Li
X, Yin Z and Liang H: Secreted clusterin gene silencing enhances
chemosensitivity of a549 cells to cisplatin through AKT and ERK1/2
pathways in vitro. Cell Physiol Biochem. 33:1162–1175. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang C, Jin G, Jin H, Wang N, Luo Q, Zhang
Y, Gao D, Jiang K, Gu D, Shen Q, et al: Clusterin facilitates
metastasis by EIF3I/Akt/MMP13 signaling in hepatocellular
carcinoma. Oncotarget. 6:2903–2916. 2015.PubMed/NCBI
|
|
24
|
Fu Y, Lai Y, Liu J, Liu X, You Z and Yang
G: Lentivirus-mediated shRNA interference of clusterin blocks
proliferation, motility, invasion and cell cycle in the ovarian
cancer cells. J Ovarian Res. 8:592015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
He J, Zhu G, Gao L, Chen P, Long Y, Liao
S, Yi H, Yi W, Pei Z, Wu M, et al: Fra-1 is upregulated in gastric
cancer tissues and affects the PI3K/Akt and p53 signaling pathway
in gastric cancer. Int J Oncol. 47:1725–1734. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Raha S, Yumnam S, Hong GE, Lee HJ,
Saralamma VV, Park HS, Heo JD, Lee SJ, Kim EH, Kim JA and Kim GS:
Naringin induces autophagy-mediated growth inhibition by
downregulating the PI3K/Akt/mTOR cascade via activation of MAPK
pathways in AGS cancer cells. Int J Oncol. 47:1061–1069. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Jin H, Qiao F, Wang Y, Xu Y and Shang Y:
Curcumin inhibits cell proliferation and induces apoptosis of human
non-small cell lung cancer cells through the upregulation of
miR-192-5p and suppression of PI3K/Akt signaling pathway. Oncol
Rep. 34:2782–2789. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lim HS, Kang YJ, Sung B, Kim SH, Kim MJ,
Kim HR, Kim SJ, Choi YH, Moon HR, Chung HY and Kim ND: Novel
dihydrobenzofuro[4,5-b][1,8]naphthyridin-6-one derivative, MHY-449,
induces cell cycle arrest and apoptosis via the downregulation of
Akt in human lung cancer cells. Oncol Rep. 34:2431–2438. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Song HB, Jun HO and Kim JH, Yu YS, Kim KW,
Min BH and Kim JH: Anti-apoptotic effect of clusterin on
cisplatin-induced cell death of retinoblastoma cells. Oncol Rep.
30:2713–2718. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wang Y, Wang X, Zhao H, Liang B and Du Q:
Clusterin confers resistance to TNF-alpha-induced apoptosis in
breast cancer cells through NF-kappaB activation and Bcl-2
overexpression. J Chemother. 24:348–357. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Lee JH, Lee JY, Rho SB, Choi JS, Lee DG,
An S, Oh T, Choi DC and Lee SH: PACAP inhibits tumor growth and
interferes with clusterin in cervical carcinomas. FEBS Lett.
588:4730–4739. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Hwang S, Lee DH, Lee IK, Park YM and Jo I:
Far-infrared radiation inhibits proliferation, migration, and
angiogenesis of human umbilical vein endothelial cells by
suppressing secretory clusterin levels. Cancer Lett. 346:74–83.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Qiu X, Cheng JC, Chang HM and Leung PC:
COX2 and PGE2 mediate EGF-induced E-cadherin-independent human
ovarian cancer cell invasion. Endocr Relat Cancer. 21:533–543.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Bhattacharya A, Li Y, Shi Y and Zhang Y:
Enhanced inhibition of urinary bladder cancer growth and muscle
invasion by allyl isothiocyanate and celecoxib in combination.
Carcinogenesis. 34:2593–2599. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Chen Z, Liu M, Liu X, Huang S, Li L, Song
B, Li H, Ren Q, Hu Z, Zhou Y and Qiao L: COX-2 regulates E-cadherin
expression through the NF-κB/Snail signaling pathway in gastric
cancer. Int J Mol Med. 32:93–100. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ammar H and Closset JL: Clusterin
activates survival through the phosphatidylinositol 3-kinase/Akt
pathway. J Biol Chem. 283:12851–12861. 2008. View Article : Google Scholar : PubMed/NCBI
|
